Surfactant protein D inhibits lipid-laden foamy macrophages and lung inflammation in chronic obstructive pulmonary disease

Hsieh, Miao-Hsi; Chen, Pei-Chi; Hsu, Hui‐Ping; Liu, Jui-Chang; Ho, Yu-Sheng; Lin, Yuh Jyh; Kuo, Chin‐Wei; Kuo, Wen-Shuo; Kao, Hui-Fang; Wang, Shulhn-Der; Liu, Zhigang; Wu, Lawrence Shih-Hsin; Wang, Jiu Yao

doi:10.1038/s41423-022-00946-2

Cited by 12 publications

(14 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a study of COPD, SP-D inhibited lipid-laden foamy macrophages (FMs), which are frequently seen under oxidative stress and have defective phagocytic functions. This study supported the essential role of SP-D in the lipid stability of alveoli and provided a possibility for the clinical application of SP-D as a treatment for lung inflammation and COPD [ 59 ]. Another study showed that recombinant SP-D inhibited influenza A virus replication, suggesting that SP-D could be utilized as a platform to develop a potential class of antiviral drugs [ 60 ].…”

Section: Recombinant Sp-d and Its Potential Benefits As A Treatment F...supporting

confidence: 65%

Circulating Surfactant Protein D: A Biomarker for Acute Lung Injury?

Elmore,

Almuntashiri,

Wang

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are life-threatening lung diseases in critically ill patients. The lack of prognostic biomarkers has halted detection methods and effective therapy development. Quantitative biomarker-based approaches in the systemic circulation have been proposed as a means of enhancing diagnostic strategies as well as pharmacotherapy in a patient-specific manner. Pulmonary surfactants are complex mixtures made up of lipids and proteins, which are secreted into the alveolar space by epithelial type II cells under normal and pathological conditions. In this review, we summarize the current knowledge of SP-D in lung injury from both preclinical and clinical studies. Among surfactant proteins, surfactant protein-D (SP-D) has been more widely studied in ALI and ARDS. Recent studies have reported that SP-D has a superior discriminatory ability compared to other lung epithelial proteins for the diagnosis of ARDS, which could reflect the severity of lung injury. Furthermore, we shed light on recombinant SP-D treatment and its benefits as a potential drug for ALI, and we encourage further studies to translate SP-D into clinical use for diagnosis and treatment.

show abstract

Section: Recombinant Sp-d and Its Potential Benefits As A Treatment F...supporting

confidence: 65%

Circulating Surfactant Protein D: A Biomarker for Acute Lung Injury?

Elmore,

Almuntashiri,

Wang

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…Indeed, in most studies, exposure to CS increased the SP-D level. Only in two studies [166,167], the SP-D level was unchanged, and in one, it was decreased [130]. As observed in humans, SP-A varied more heterogeneously after CS exposure, decreasing in three studies, increasing in three others and remaining unchanged in one.…”

Section: Cigarette Smoke Effect's On Composition and Abundance Of Sur...mentioning

confidence: 69%

“…Many animal studies have shown a protective effect of SP-D against oxidative stress, inflammation, autophagy and apoptosis induced by CS. This has been demonstrated by administering recombinant SP-D [92,167], by studying the effects of smoking on SP-D-deficient mice [92,167] or by transfecting SP-D plasmid DNA into A-549 cells [168]. According to these studies, increased SP-D levels after exposure to CS would therefore be a positive and protective response against smoking-induced damage.…”

Section: Cigarette Smoke Effect's On Composition and Abundance Of Sur...mentioning

confidence: 99%

Molecular Impact of Conventional and Electronic Cigarettes on Pulmonary Surfactant

Garavaglia

Bodega

Porta

et al. 2023

IJMS

View full text Add to dashboard Cite

The alveolar epithelium is covered by a non-cellular layer consisting of an aqueous hypophase topped by pulmonary surfactant, a lipo-protein mixture with surface-active properties. Exposure to cigarette smoke (CS) affects lung physiology and is linked to the development of several diseases. The macroscopic effects of CS are determined by several types of cell and molecular dysfunction, which, among other consequences, lead to surfactant alterations. The purpose of this review is to summarize the published studies aimed at uncovering the effects of CS on both the lipid and protein constituents of surfactant, discussing the molecular mechanisms involved in surfactant homeostasis that are altered by CS. Although surfactant homeostasis has been the topic of several studies and some molecular pathways can be deduced from an analysis of the literature, it remains evident that many aspects of the mechanisms of action of CS on surfactant homeostasis deserve further investigation.

show abstract

“…Исследования показывают, что синтезированные формы и рекомбинантные фрагменты SP-A и SP-D могут быть применимы для терапевтического использования [23]. Преимущество рекомбинантных фрагментов SP-D в их меньшем размере, тем самым увеличивается вероятность достижения дистальных отделов легких и демонстрируется более высокая устойчивость к протеазам и коллагеназам, чем полноразмерные SP-D [24]. В связи с этим, синтезированные формы и рекомбинантные фрагменты SP-A и SP-D могут рассматриваться в дополнение к естественным легочным поверхностно-активным веществам.…”

Section: Pulmonologyunclassified

The use of exogenous surfactant in pulmonological practice

Ignatova,

Antonov,

Zakharova

2024

Medicinskij sovet

View full text Add to dashboard Cite

A lung surfactant is a complex mixture of lipids and proteins necessary to maintain proper lung function. Drug changes play an important role in chronic lung diseases such as chronic obstructive pulmonary disease, bronchial asthma and idiopathic pulmonary fibrosis. The purpose of this article is to substantiate the use of exogenous surfactant in various respiratory diseases, based on the analysis of publications in domestic and international medical journals, as well as their own experience of application in real clinical practice. This review primarily discusses the contribution of pulmonary surfactants to maintaining homeostasis of the respiratory system; optimal delivery routes; differences between natural and synthetic surfactant; diseases associated with impaired surfactant production, such as idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease, acute respiratory distress syndrome, pulmonary alveolar proteinosis, cystic fibrosis. Special attention is paid to the immunological properties of specific proteins of surfactants A and D, their effect on protection against respiratory viral infection. Data on the direct effect of exogenous surfactant on pulmonary function, an increase in post-bronchodilation FEV1 and FVC are presented. Special attention is paid to the use of surfactant in the new coronavirus infection COVID-19. Pharmacological and therapeutic strategies to improve pulmonary surfactant dysfunction can prevent alveolar collapse, reduce the proinflammatory response, and limit viral infection. Currently, the use of surfactant preparations for the treatment of various respiratory diseases is being studied in several clinical trials, which will significantly revise the understanding of the therapeutic possibilities of an exogenous surfactant and expand its application areas.

show abstract

Surfactant protein D inhibits lipid-laden foamy macrophages and lung inflammation in chronic obstructive pulmonary disease

Cited by 12 publications

References 43 publications

Circulating Surfactant Protein D: A Biomarker for Acute Lung Injury?

Circulating Surfactant Protein D: A Biomarker for Acute Lung Injury?

Molecular Impact of Conventional and Electronic Cigarettes on Pulmonary Surfactant

The use of exogenous surfactant in pulmonological practice

Contact Info

Product

Resources

About